• A Russo, M Falcone, B Gutiérrez-Gutiérrez, E Calbo, B Almirante, P L Viale, A Oliver, P Ruiz-Garbajosa, O Gasch, M Gozalo, J Pitout, M Akova, C Peña, J M Cisneros, A Hernández-Torres, A Farcomeni, N Prim, J Origüen, G Bou, E Tacconelli, M Tumbarello, A Hamprecht, I Karaiskos, C de la Calle, F Pérez, M J Schwaber, J Bermejo, W Lowman, P-R Hsueh, M Mora-Rillo, J Rodriguez-Gomez, M Souli, R A Bonomo, D L Paterson, Y Carmeli, A Pascual, J Rodríguez-Baño, M Venditti, and REIPI/ESGBIS/INCREMENT investigators.
• Department of Public Health and Infectious Diseases, Policlinico Umberto I, University of Rome La Sapienza, Rome, Italy.
• Int. J. Antimicrob. Agents. 2018 Nov 1; 52 (5): 577-585.

PurposeThere are few data in the literature regarding sepsis or septic shock due to extended-spectrum β-lactamases (ESBL)-producing Enterobacteriaceae (E). The aim of this study was to assess predictors of outcome in septic patients with bloodstream infection (BSI) caused by ESBL-E.MethodsPatients with severe sepsis or septic shock and BSI due to ESBL-E were selected from the INCREMENT database. The primary endpoint of the study was the evaluation of predictors of outcome after 30 days from development of severe sepsis or septic shock due to ESBL-E infection. Three cohorts were created for analysis: global, empirical-therapy and targeted-therapy cohorts.Results367 septic patients were analysed. Overall mortality was 43.9% at 30 days. Escherichia coli (62.4%) and Klebsiella pneumoniae (27.2%) were the most frequent isolates. β-lactam/β-lactamase inhibitor (BLBLI) combinations were the most empirically used drug (43.6%), followed by carbapenems (29.4%). Empirical therapy was active in vitro in 249 (67.8%) patients, and escalation of antibiotic therapy was reported in 287 (78.2%) patients. Cox regression analysis showed that age, Charlson Comorbidity Index, McCabe classification, Pitt bacteremia score, abdominal source of infection and escalation of antibiotic therapy were independently associated with 30-day mortality. No differences in survival were reported in patients treated with BLBLI combinations or carbapenems in empirical or definitive therapy.ConclusionsBSI due to ESBL-E in patients who developed severe sepsis or septic shock was associated with high 30-day mortality. Comorbidities, severity scores, source of infection and antibiotic therapy escalation were important determinants of unfavorable outcome.Copyright © 2018 Elsevier Ltd. All rights reserved.

36 keywords...

hide…